1. Clinical approach on challenge and desensitization procedures with aspirin in patients with ischemic heart disease and nonsteroidal anti-inflammatory drug hypersensitivity
- Author
-
Cortellini, G, Romano, A, Santucci, A, Barbaud, A, Bavbek, S, Bignardi, D, Blanca, M, Bonadonna, P, Costantino, M T, Laguna, J J, Lombardo, C, Losappio, L M, Makowska, J, Nakonechna, A, Quercia, O, Pastorello, E A, Patella, V, Terreehorst, I, Testi, S, Cernadas, J R, EAACI Drug Interest Group on Challenge and Desensitization Procedures with Aspirin in CAD, Dionicio Elera, J, Lippolis, D, Voltolini, S, Grosseto, D, Paediatric Pulmonology, Ear, Nose and Throat, and Amsterdam Cardiovascular Sciences
- Subjects
Male ,Acute coronary syndrome ,Allergy ,aspirin ,medicine.medical_treatment ,Immunology ,Clinical Decision-Making ,Myocardial Ischemia ,challenge procedure ,Comorbidity ,030204 cardiovascular system & hematology ,nonsteroidal anti-inflammatory drugs hypersensitivity ,Bronchospasm ,Coronary artery disease ,Drug Hypersensitivity ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Immunology and Allergy ,Humans ,Desensitization (medicine) ,Aged ,Aspirin ,Angioedema ,business.industry ,Settore MED/09 - MEDICINA INTERNA ,Anti-Inflammatory Agents, Non-Steroidal ,Middle Aged ,medicine.disease ,desensitization procedure ,Treatment Outcome ,030228 respiratory system ,Desensitization, Immunologic ,Anesthesia ,Female ,medicine.symptom ,business ,Anaphylaxis ,Algorithms ,medicine.drug - Abstract
Background Hypersensitivity to acetylsalicylic acid (ASA) constitutes a serious problem for subjects with coronary artery disease. In such subjects, physicians have to choose the more appropriate procedure between challenge and desensitization. As the literature on this issue is sparse, the present study aims to establish in these subjects clinical criteria for eligibility for an ASA challenge and/or desensitization. Methods Collection and analysis of data on ASA challenges and desensitizations from 10 allergy centers, as well as consensus among the related physicians and an expert panel. Results Altogether, 310 subjects were assessed; 217 had histories of urticaria/angioedema, 50 of anaphylaxis, 26 of non-immediate cutaneous eruptions, and 17 of bronchospasm related to ASA/NSAID intake. Specifically, 119 subjects had index reactions to ASA doses lower than 300 mg. Of the 310 subjects, 138 had an acute coronary syndrome (ACS), 101 of whom underwent desensitizations, whereas 172 suffered from a chronic ischemic heart disease (CIHD), 126 of whom underwent challenges. Overall, 163 subjects underwent challenges and 147 desensitizations; 86 of the latter had index reactions to ASA doses of 300 mg or less. Ten subjects reacted to challenges, 7 at doses up to 500 mg, 3 at a cumulative dose of 110 mg. The desensitization failure rate was 1.4%. Conclusions In patients with stable CIHD and histories of non-severe hypersensitivity reactions to ASA/NSAIDs, an ASA challenge is advisable. Patients with an ACS and histories of hypersensitivity reactions to ASA, especially following doses lower than 100 mg, should directly undergo desensitization. This article is protected by copyright. All rights reserved.
- Published
- 2017